Bozic Carmen 4

What Happened

• Carmen Bozic, EVP and Chief Medical Officer of Vertex Pharmaceuticals (VRTX), received a grant of 5,375 restricted stock units (RSUs) on Feb 17, 2026 (reported as acquisition code A, $0.00 per share on the Form 4). On the same date, 1,912 shares were disposed under code F (payment of tax liability), reported at $483.75 per share for a total of $924,930. The disposal appears to be a tax-withholding/covering transaction tied to the RSU award.

Key Details

• Transaction date: February 17, 2026; Form 4 filed February 19, 2026 (appears timely).
• Grant: 5,375 RSUs (code A), reported at $0.00 on the Form 4.
• Tax withholding: 1,912 shares surrendered/disposed (code F) at $483.75 each, total ~$924,930.
• Vesting note: Footnote indicates the RSU award vests in installments beginning February 20, 2027.
• Shares owned after the transactions: Not specified in this filing.
• Interpretation: Code F indicates shares were used to satisfy tax obligations (common for RSU grants), not an open-market sale signaling a change in investment view.

Context

• This combination of an RSU grant and same-day share withholding is a routine compensation event: companies often withhold or sell a portion of awarded shares to cover taxes when RSUs are granted or vest. Such transactions typically reflect tax mechanics rather than a direct buy/sell decision by the insider.